 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the [0m
[34mrisk of renal failure?[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the [0m
[32mrisk of renal failure?[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"EXTENDED PHENYTOIN SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: EXTENDED PHENYTOIN SODIUM: geriatric_use: [0m[1;31m8.5[0m[31m Geriatric Use Phenytoin clearance tends to decrease with increasing age [0m[31m. Lower or less frequent dosing may be required [0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide: Extended phenytoin sodium capsules can cause problems with your heart, including a slow heartbeat. Let your healthcare provider know right away if you[0m
[31mhave any of these symptoms: dizziness tiredness feeling like your heart is beating slowly or skipping beats chest pain What are extended phenytoin sodium capsules? Extended phenytoin sodium capsules [0m
[31mare a prescription medicine used to treat certain types of seizures called tonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures. Do not take extended phenytoin sodium capsules if you: Are[0m
[31mallergic to phenytoin or any of the ingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules. Have had an[0m
[31mallergic reaction to CEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide: Have had liver problems from taking phenytoin. Take delavirdine. [0m
[31mBefore taking extended phenytoin sodium capsules, tell your healthcare provider about all of your medical conditions, including if you: Have or have had depression, mood problems, or suicidal thoughts[0m
[31mor behavior Have had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones Have or had liver or kidney[0m
[31mproblems Have or had an enzyme problem called porphyria Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m Drink alcohol Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm [0m
[31myour unborn baby. If you take extended phenytoin sodium capsules during pregnancy, your baby is at risk for serious birth defects. EXTENDED PHENYTOIN SODIUM: spl_medguide: If you become pregnant while[0m
[31mtaking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease, causing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin[0m
[31msodium capsules. If you take extended phenytoin sodium capsules during pregnancy, your baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby[0m
[31mmedicine to prevent this. All women of child-bearing age should talk to their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. If you are of [0m
[31mchildbearing age and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules. Pregnancy Registry: If you become [0m
[31mpregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. EXTENDED PHENYTOIN SODIUM: [0m
[31mspl_medguide: You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. These medicines can change the [0m
[31mlevels of phenytoin in your blood. Taking extended phenytoin sodium capsules with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines [0m
[31mwithout talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take [0m
[31mextended phenytoin sodium capsules? EXTENDED PHENYTOIN SODIUM: spl_medguide: Take extended phenytoin sodium capsules exactly as your healthcare provider tells you. Your healthcare provider will tell [0m
[31myou how much extended phenytoin sodium capsules to take and when to take it. Your healthcare provider may change your dose if needed. Do not change your dose of extended phenytoin sodium capsules [0m
[31mwithout talking to your healthcare provider. Do not stop taking extended phenytoin sodium capsules without first talking to your healthcare provider. Stopping extended phenytoin sodium capsules [0m
[31msuddenly can cause serious problems. What should I avoid while taking extended phenytoin sodium capsules? Do not drink alcohol while you take extended phenytoin sodium capsules without first talking [0m
[31mto your healthcare provider. Drinking alcohol while taking extended phenytoin sodium capsules may change your blood levels of phenytoin which can cause serious problems. Do not drive, operate heavy [0m
[31mmachinery, or do other dangerous activities until you know how extended phenytoin sodium capsules affects you. EXTENDED PHENYTOIN SODIUM: spl_medguide: Extended phenytoin sodium capsules can slow your[0m
[31mthinking and motor skills. What are the possible side effects of extended phenytoin sodium capsules? See ‚Äú What is the most important information I should know about extended phenytoin sodium [0m
[31mcapsules?‚Äù Extended phenytoin sodium capsules may cause other serious side effects including: Liver problems. Low blood count which could increase your chance of getting infections, bruising, bleeding[0m
[31mand increased fatigue. Softening of your bones [0m[1;31m([0m[31mosteopenia, osteoporosis, and osteomalacia[0m[1;31m)[0m[31m can cause your bones to break [0m[1;31m([0m[31mfractures[0m[1;31m)[0m[31m. High blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m. High levels of phenytoin in [0m
[31myour blood that could cause confusion also known as delirium, psychosis or a more serious condition that affects how your brain works [0m[1;31m([0m[31mencephalopathy[0m[1;31m)[0m[31m. Call your healthcare provider right away, if you[0m
[31mhave any of the symptoms listed above. EXTENDED PHENYTOIN SODIUM: spl_medguide: The most common side effects of extended phenytoin sodium capsules include: Irregular movement of the eye [0m[1;31m([0m[31mnystagmus[0m[1;31m)[0m[31m [0m
[31mSlurred speech Drowsiness [0m[1;31m([0m[31msomnolence[0m[1;31m)[0m[31m Problems with movement and balance [0m[1;31m([0m[31mataxia[0m[1;31m)[0m[31m Decrease in coordination Confusion Extended phenytoin sodium capsules can cause overgrowth of your gums. Brushing and[0m
[31mflossing your teeth and seeing a dentist regularly while taking extended phenytoin sodium capsules can help prevent this from happening. These are not all of the possible side effects of extended [0m
[31mphenytoin sodium capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How should I store extended phenytoin sodium capsules? Store [0m
[31mextended phenytoin sodium capsules at room temperature between [0m[1;31m68[0m[31m¬∞F to [0m[1;31m77[0m[31m¬∞F [0m[1;31m([0m[1;31m20[0m[31m¬∞C to [0m[1;31m25[0m[31m¬∞C[0m[1;31m)[0m[31m. Store in tight, light-resistant containers. Protect from moisture. EXTENDED PHENYTOIN SODIUM: spl_medguide: [0m
[31mKeep extended phenytoin sodium capsules and all medicines out of the reach of children. General information about the safe and effective use of extended phenytoin sodium capsules. Medicines are [0m
[31msometimes prescribed for purposes other than those listed in a Medication Guide. Do not use extended phenytoin sodium capsules for a condition for which it was not prescribed. Do not give extended [0m
[31mphenytoin sodium capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about extended [0m
[31mphenytoin sodium capsules that is written for health professionals. What are the ingredients in extended phenytoin sodium capsules? Extended phenytoin sodium capsules [0m[1;31m100[0m[31m mg: white opaque/light [0m
[31mlavender opaque, hard gelatin capsules imprinted with [0m[31m"IP 212"[0m[31m on both cap and body. EXTENDED PHENYTOIN SODIUM: spl_medguide: Active ingredient: [0m[1;31m100[0m[31m mg phenytoin sodium, USP Inactive ingredients: D&C [0m
[31mRed #[0m[1;31m28[0m[31m, D&C Red #[0m[1;31m33[0m[31m, FD&C Blue #[0m[1;31m1[0m[31m, gelatin, hydroxypropyl cellulose, mannitol, magnesium stearate, talc and titanium dioxide. For more information about extended phenytoin sodium capsules, visit [0m
[31mwww.amneal.com or call [0m[1;31m1[0m[31m-[0m[1;31m877[0m[31m-[0m[1;31m835[0m[31m-[0m[1;31m5472[0m[31m. This Medication Guide has been approved by the U.S. Food and Drug Administration. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ [0m[1;31m08807[0m[31m Rev. EXTENDED [0m
[31mPHENYTOIN SODIUM: spl_medguide: [0m[1;31m08[0m[31m-[0m[1;31m2023[0m[31m-[0m[1;31m07[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: information_for_patients: Use in Pregnancy Inform pregnant women and women of childbearing potential that use of phenytoin during pregnancy can cause fetal harm, [0m
[31mincluding an increased risk for cleft lip and/or cleft palate [0m[1;31m([0m[31moral clefts[0m[1;31m)[0m[31m, cardiac defects, dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding [0m
[31mmicrocephaly[0m[1;31m)[0m[31m, and cognitive deficits. When appropriate, counsel pregnant women and women of childbearing potential about alternative therapeutic options. Advise women of childbearing potential who [0m
[31mare not planning a pregnancy to use effective contraception while using phenytoin, keeping in mind that there is a potential for decreased hormonal contraceptive efficacy [0m[31m. Instruct patients to notify[0m
[31mtheir physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breastfeeding or intend to breastfeed during therapy [0m[31m . EXTENDED [0m
[31mPHENYTOIN SODIUM: information_for_patients: Encourage patients to enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry if they become pregnant. This registry is collecting [0m
[31minformation about the safety of antiepileptic drugs during pregnancy [0m[31m . Brands listed are the trademarks of their respective owners. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ [0m[1;31m08807[0m[31m [0m
[31mRev. EXTENDED PHENYTOIN SODIUM: information_for_patients: [0m[1;31m08[0m[31m-[0m[1;31m2023[0m[31m-[0m[1;31m09[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide_table: content>[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Extended phenytoin sodium capsules are a prescription medicine used to treat certain types of seizures called [0m
[31mtonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not [0m
[31mtake<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Are allergic to phenytoin or any of the [0m
[31mingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to [0m
[31mCEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>Have had liver problems from taking phenytoin.<[0m[31m/[0m[31mitem[0m[31m><item>Take [0m
[31mdelavirdine.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Before taking<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules, tell your healthcare provider about all of your [0m
[31mmedical conditions, including if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Have or have had depression, mood problems, or suicidal thoughts or [0m
[31mbehavior<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones<[0m[31m/[0m[31mitem[0m[31m><item>Have [0m
[31mor had liver or kidney problems<[0m[31m/[0m[31mitem[0m[31m><item>Have or had an enzyme problem called porphyria<[0m[31m/[0m[31mitem[0m[31m><item>Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>Drink alcohol<[0m[31m/[0m[31mitem[0m[31m><item EXTENDED [0m
[31mPHENYTOIN SODIUM: spl_medguide_table: >Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm your unborn baby.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules[0m
[31mduring pregnancy, your baby is at risk for serious birth defects.<[0m[31m/[0m[31mitem[0m[31m><item>If you become pregnant while taking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease,[0m
[31mcausing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules during pregnancy,[0m
[31myour baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby medicine to prevent this.<[0m[31m/[0m[31mitem[0m[31m><item>All women of child-bearing age should talk [0m
[31mto their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>If you are of childbearing [0m
[31mage and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Pregnancy [0m
[31mRegistry:<[0m[31m/[0m[31mcontent[0m[31m>If you become pregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy [0m
[31mRegistry. You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. <[0m[31m/[0m[31mitem[0m[31m><item>Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><[0m[31m/[0m[31mlist[0m[31m><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter [0m
[31mmedicines, vitamins, and herbal supplements. These medicines can change the levels of phenytoin in your blood.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Taking extended phenytoin sodium capsules with certain other [0m
[31mmedicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Know the medicines you take. Keep[0m
[31ma list of them and show it to your healthcare provider and pharmacist when you get a new medicine.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How should I take<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules?         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: drug_interactions: John‚Äôs wort b , sucralfate, theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, [0m
[31mvalproate sodium c , valproic acid c a Antacids may affect absorption of phenytoin. b The induction potency of St. John‚Äôs wort may vary widely based on preparation. c Valproate sodium and valproic [0m
[31macid are similar medications. The term valproate has been used to represent these medications. [0m[1;31m7.2[0m[31m Drugs Affected by Phenytoin Table [0m[1;31m3[0m[31m includes commonly occurring drug interactions affected by [0m
[31mphenytoin. However, this list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted. The addition or withdrawal of phenytoin during concomitant therapy [0m
[31mwith these agents may require adjustment of the dose of these agents to achieve optimal clinical outcome. EXTENDED PHENYTOIN SODIUM: drug_interactions: Table [0m[1;31m3[0m[31m: Drugs Affected by Phenytoin Interacting[0m
[31mAgent Examples Drugs whose efficacy is impaired by phenytoin Azoles Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole Antineoplastic agents Irinotecan, paclitaxel, teniposide [0m
[31mDelavirdine Phenytoin can substantially reduce the concentrations of delavirdine. This can lead to loss of virologic response and possible resistance [0m[31m. Neuromuscular blocking agents Cisatracurium, [0m
[31mpancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered [0m
[31mphenytoin. Whether or not phenytoin has the same effect on other non-depolarizing agents is unknown. EXTENDED PHENYTOIN SODIUM: drug_interactions: Prevention or Management: Patients should be [0m
[31mmonitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher. EXTENDED PHENYTOIN SODIUM: drug_interactions: Warfarin Increased and [0m
[31mdecreased PT/INR responses have been reported when phenytoin is co-administered with warfarin Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, [0m
[31mrifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs a Carbamazepine, felbamate,[0m
[31mlamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, [0m
[31mnelfin EXTENDED PHENYTOIN SODIUM: drug_interactions: avir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active [0m
[31mmetabolite. Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, [0m
[31mverapamil Other Albendazole [0m[1;31m([0m[31mdecreases active metabolite[0m[1;31m)[0m[31m, chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine a The effect of [0m
[31mphenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable [0m[1;31m7[0m[31m. EXTENDED PHENYTOIN SODIUM: drug_interactions: [0m[1;31m3[0m[31m Hyperammonemia with Concomitant Use of Valproate [0m
[31mConcomitant administration of phenytoin and valproate has been associated with an increased risk of valproate-associated hyperammonemia. Patients treated concomitantly with these two drugs should be [0m
[31mmonitored for signs and symptoms of hyperammonemia. [0m[1;31m7.4[0m[31m Drug Enteral Feeding/Nutritional Preparations Interaction Literature reports suggest that patients who have received enteral feeding [0m
[31mpreparations and/or related nutritional supplements have lower than expected phenytoin serum levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding [0m
[31mpreparation. More frequent serum phenytoin level monitoring may be necessary in these patients. [0m[1;31m7.5[0m[31m Drug/Laboratory Test Interactions Care should be taken when using immunoanalytical methods to [0m
[31mmeasure serum phenytoin concentrations.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: drug_interactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Warfarin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Increased and decreased PT/INR responses have been [0m
[31mreported when phenytoin is co-administered with warfarin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Other<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Corticosteroids, doxycycline, estrogens, furosemide, oral [0m
[31mcontraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Drugs whose level is decreased by[0m
[31mphenytoin<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Anticoagulants<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Apixaban, dabigatran, edoxaban, rivaroxaban EXTENDED PHENYTOIN SODIUM: [0m
[31mdrug_interactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antiepileptic drugs <sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, [0m
[31mlacosamide<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antilipidemic agents<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Atorvastatin, fluvastatin, [0m
[31msimvastatin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antiplatelets<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Ticagrelor<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antiviral [0m
[31magents<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Fosamp EXTENDED PHENYTOIN SODIUM: drug_interactions_table: [0m
[31mrenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. EXTENDED PHENYTOIN SODIUM: drug_interactions_table: Phenytoin when given [0m
[31mwith the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Calcium channel [0m
[31mblockers<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Nifedipine, nimodipine, nisoldipine, verapamil<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Other<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Albendazole [0m[1;31m([0m[31mdecreases active [0m
[31mmetabolite[0m[1;31m)[0m[31m, chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"EXTENDED PHENYTOIN SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does EXTENDED PHENYTOIN SODIUM increase or decrease [0m
[31mthe risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does extended phenytoin sodium increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes extended phenytoin sodium increase or decrease the [0m
[32mrisk of renal failure?[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes extended phenytoin sodium increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does extended phenytoin sodium increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"extended phenytoin sodium"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: EXTENDED PHENYTOIN SODIUM: geriatric_use: [0m[1;31m8.5[0m[31m Geriatric Use Phenytoin clearance tends to decrease with increasing age [0m[31m. Lower or less frequent dosing may be required [0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other [0m
[31madverse developmental outcomes. [0m[1;31m([0m[31m [0m[1;31m5.13[0m[31m , [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. [0m[1;31m([0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy Pregnancy Exposure [0m
[31mRegistry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such as phenytoin sodium, during pregnancy. Physicians are advised to [0m
[31mrecommend that pregnant patients taking phenytoin sodium enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry. This can be done by calling the toll free number [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, [0m
[31mand must be done by patients themselves. Information on the registry can also be found at the website [0m[4;31mhttp://www.[0m[31m EXTENDED PHENYTOIN SODIUM: use_in_specific_populations: edpregnancyregistry.org/ Risk [0m
[31mSummary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal phenytoin exposure is associated with an [0m
[31mincreased incidence of major malformations, including orofacial clefts and cardiac defects. In addition, the fetal hydantoin syndrome, a pattern of abnormalities including dysmorphic skull and facial [0m
[31mfeatures, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among children born to epileptic women who took phenytoin alone or in [0m
[31mcombination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including neuroblastoma, in children whose mothers received phenytoin during [0m
[31mpregnancy. EXTENDED PHENYTOIN SODIUM: use_in_specific_populations: Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other manifestations of[0m
[31mdevelopmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general population, the estimated [0m
[31mbackground risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. The background risk of major birth defects and miscarriage for [0m
[31mthe indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics.[0m
[31mPeriodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage [0m[31m .         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: These events may be part of the spectrum of DRESS or may occur in isolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, [0m
[31melevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute [0m
[31mhepatotoxicity, phenytoin sodium should be immediately discontinued and not readministered. [0m[1;31m5.9[0m[31m Hematopoietic Complications Hematopoietic complications, some fatal, have occasionally been reported in [0m
[31massociation with administration of phenytoin sodium. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. [0m
[31mEXTENDED PHENYTOIN SODIUM: warnings_and_cautions: There have been a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m [0m
[31mincluding benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin‚Äôs disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates[0m
[31mthe need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs of DRESS [0m[31m . In all cases of lymphadenopathy, [0m
[31mfollow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs. [0m[1;31m5.10[0m[31m Effects on Vitamin D and Bone The [0m
[31mchronic use of phenytoin in patients with epilepsy has been associated with decreased bone mineral density [0m[1;31m([0m[31mosteopenia, osteoporosis, and osteomalacia[0m[1;31m)[0m[31m and bone fractures. EXTENDED PHENYTOIN SODIUM: [0m
[31mwarnings_and_cautions: Phenytoin induces hepatic metabolizing enzymes. This may enhance the metabolism of vitamin D and decrease vitamin D levels, which may lead to vitamin D deficiency, hypocalcemia,[0m
[31mand hypophosphatemia. Consideration should be given to screening with bone-related laboratory and radiological tests as appropriate and initiating treatment plans according to established guidelines. [0m
[1;31m5.11[0m[31m Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring [0m
[31mof phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m5.12[0m[31m Exacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, [0m
[31mcaution should be exercised in using this medication in patients suffering from this disease. [0m[1;31m5[0m[31m. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m13[0m[31m Teratogenicity and Other Harm to the Newborn [0m
[31mPhenytoin may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes [0m[31m. [0m
[31mIncreased frequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac defects[0m[1;31m)[0m[31m, and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial [0m
[31mfeatures, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in [0m
[31mcombination with other antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including neuroblastoma. EXTENDED PHENYTOIN SODIUM: warnings_and_cautions: A [0m
[31mpotentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can[0m
[31mbe prevented with vitamin K administration to the mother before delivery and to the neonate after birth. [0m[1;31m5.14[0m[31m Hyperglycemia Hyperglycemia, resulting from the drug‚Äôs inhibitory effects on insulin [0m
[31mrelease, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients. [0m[1;31m5.15[0m[31m Serum Phenytoin Levels above Therapeutic Range Serum levels of phenytoin sustained above the [0m
[31mtherapeutic range may produce confusional states referred to as ‚Äúdelirium,‚Äù ‚Äúpsychosis,‚Äù or ‚Äúencephalopathy,‚Äù or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at [0m
[31mthe first sign of acute toxicity, serum levels should be immediately checked.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide: Extended phenytoin sodium capsules can cause problems with your heart, including a slow heartbeat. Let your healthcare provider know right away if you[0m
[31mhave any of these symptoms: dizziness tiredness feeling like your heart is beating slowly or skipping beats chest pain What are extended phenytoin sodium capsules? Extended phenytoin sodium capsules [0m
[31mare a prescription medicine used to treat certain types of seizures called tonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures. Do not take extended phenytoin sodium capsules if you: Are[0m
[31mallergic to phenytoin or any of the ingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules. Have had an[0m
[31mallergic reaction to CEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide: Have had liver problems from taking phenytoin. Take delavirdine. [0m
[31mBefore taking extended phenytoin sodium capsules, tell your healthcare provider about all of your medical conditions, including if you: Have or have had depression, mood problems, or suicidal thoughts[0m
[31mor behavior Have had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones Have or had liver or kidney[0m
[31mproblems Have or had an enzyme problem called porphyria Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m Drink alcohol Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm [0m
[31myour unborn baby. If you take extended phenytoin sodium capsules during pregnancy, your baby is at risk for serious birth defects. EXTENDED PHENYTOIN SODIUM: spl_medguide: If you become pregnant while[0m
[31mtaking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease, causing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin[0m
[31msodium capsules. If you take extended phenytoin sodium capsules during pregnancy, your baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby[0m
[31mmedicine to prevent this. All women of child-bearing age should talk to their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. If you are of [0m
[31mchildbearing age and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules. Pregnancy Registry: If you become [0m
[31mpregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. EXTENDED PHENYTOIN SODIUM: [0m
[31mspl_medguide: You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. These medicines can change the [0m
[31mlevels of phenytoin in your blood. Taking extended phenytoin sodium capsules with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines [0m
[31mwithout talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take [0m
[31mextended phenytoin sodium capsules? EXTENDED PHENYTOIN SODIUM: spl_medguide: Take extended phenytoin sodium capsules exactly as your healthcare provider tells you. Your healthcare provider will tell [0m
[31myou how much extended phenytoin sodium capsules to take and when to take it. Your healthcare provider may change your dose if needed. Do not change your dose of extended phenytoin sodium capsules [0m
[31mwithout talking to your healthcare provider. Do not stop taking extended phenytoin sodium capsules without first talking to your healthcare provider. Stopping extended phenytoin sodium capsules [0m
[31msuddenly can cause serious problems. What should I avoid while taking extended phenytoin sodium capsules? Do not drink alcohol while you take extended phenytoin sodium capsules without first talking [0m
[31mto your healthcare provider. Drinking alcohol while taking extended phenytoin sodium capsules may change your blood levels of phenytoin which can cause serious problems. Do not drive, operate heavy [0m
[31mmachinery, or do other dangerous activities until you know how extended phenytoin sodium capsules affects you. EXTENDED PHENYTOIN SODIUM: spl_medguide: Extended phenytoin sodium capsules can slow your[0m
[31mthinking and motor skills. What are the possible side effects of extended phenytoin sodium capsules? See ‚Äú What is the most important information I should know about extended phenytoin sodium [0m
[31mcapsules?‚Äù Extended phenytoin sodium capsules may cause other serious side effects including: Liver problems. Low blood count which could increase your chance of getting infections, bruising, bleeding[0m
[31mand increased fatigue. Softening of your bones [0m[1;31m([0m[31mosteopenia, osteoporosis, and osteomalacia[0m[1;31m)[0m[31m can cause your bones to break [0m[1;31m([0m[31mfractures[0m[1;31m)[0m[31m. High blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m. High levels of phenytoin in [0m
[31myour blood that could cause confusion also known as delirium, psychosis or a more serious condition that affects how your brain works [0m[1;31m([0m[31mencephalopathy[0m[1;31m)[0m[31m. Call your healthcare provider right away, if you[0m
[31mhave any of the symptoms listed above. EXTENDED PHENYTOIN SODIUM: spl_medguide: The most common side effects of extended phenytoin sodium capsules include: Irregular movement of the eye [0m[1;31m([0m[31mnystagmus[0m[1;31m)[0m[31m [0m
[31mSlurred speech Drowsiness [0m[1;31m([0m[31msomnolence[0m[1;31m)[0m[31m Problems with movement and balance [0m[1;31m([0m[31mataxia[0m[1;31m)[0m[31m Decrease in coordination Confusion Extended phenytoin sodium capsules can cause overgrowth of your gums. Brushing and[0m
[31mflossing your teeth and seeing a dentist regularly while taking extended phenytoin sodium capsules can help prevent this from happening. These are not all of the possible side effects of extended [0m
[31mphenytoin sodium capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How should I store extended phenytoin sodium capsules? Store [0m
[31mextended phenytoin sodium capsules at room temperature between [0m[1;31m68[0m[31m¬∞F to [0m[1;31m77[0m[31m¬∞F [0m[1;31m([0m[1;31m20[0m[31m¬∞C to [0m[1;31m25[0m[31m¬∞C[0m[1;31m)[0m[31m. Store in tight, light-resistant containers. Protect from moisture. EXTENDED PHENYTOIN SODIUM: spl_medguide: [0m
[31mKeep extended phenytoin sodium capsules and all medicines out of the reach of children. General information about the safe and effective use of extended phenytoin sodium capsules. Medicines are [0m
[31msometimes prescribed for purposes other than those listed in a Medication Guide. Do not use extended phenytoin sodium capsules for a condition for which it was not prescribed. Do not give extended [0m
[31mphenytoin sodium capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about extended [0m
[31mphenytoin sodium capsules that is written for health professionals. What are the ingredients in extended phenytoin sodium capsules? Extended phenytoin sodium capsules [0m[1;31m100[0m[31m mg: white opaque/light [0m
[31mlavender opaque, hard gelatin capsules imprinted with [0m[31m"IP 212"[0m[31m on both cap and body. EXTENDED PHENYTOIN SODIUM: spl_medguide: Active ingredient: [0m[1;31m100[0m[31m mg phenytoin sodium, USP Inactive ingredients: D&C [0m
[31mRed #[0m[1;31m28[0m[31m, D&C Red #[0m[1;31m33[0m[31m, FD&C Blue #[0m[1;31m1[0m[31m, gelatin, hydroxypropyl cellulose, mannitol, magnesium stearate, talc and titanium dioxide. For more information about extended phenytoin sodium capsules, visit [0m
[31mwww.amneal.com or call [0m[1;31m1[0m[31m-[0m[1;31m877[0m[31m-[0m[1;31m835[0m[31m-[0m[1;31m5472[0m[31m. This Medication Guide has been approved by the U.S. Food and Drug Administration. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ [0m[1;31m08807[0m[31m Rev.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: drug_interactions: Prevention or Management: Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion [0m
[31mrate requirements may be higher. EXTENDED PHENYTOIN SODIUM: drug_interactions: Warfarin Increased and decreased PT/INR responses have been reported when phenytoin is co-administered with warfarin [0m
[31mOther Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin [0m
[31mAnticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs a Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, [0m
[31mfluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfin EXTENDED PHENYTOIN SODIUM: drug_interactions: avir, ritonavir, saquinavir [0m
[31mFosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. Phenytoin when given with the combination of fosamprenavir and [0m
[31mritonavir may increase the concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil Other Albendazole [0m[1;31m([0m[31mdecreases active metabolite[0m[1;31m)[0m[31m, chlorpropamide, [0m
[31mclozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine a The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels [0m
[31mis unpredictable [0m[1;31m7[0m[31m. EXTENDED PHENYTOIN SODIUM: drug_interactions: [0m[1;31m3[0m[31m Hyperammonemia with Concomitant Use of Valproate Concomitant administration of phenytoin and valproate has been associated with an [0m
[31mincreased risk of valproate-associated hyperammonemia. Patients treated concomitantly with these two drugs should be monitored for signs and symptoms of hyperammonemia. [0m[1;31m7.4[0m[31m Drug Enteral [0m
[31mFeeding/Nutritional Preparations Interaction Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected [0m
[31mphenytoin serum levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary [0m
[31min these patients. [0m[1;31m7.5[0m[31m Drug/Laboratory Test Interactions Care should be taken when using immunoanalytical methods to measure serum phenytoin concentrations.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: spl_medguide_table: content>[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Extended phenytoin sodium capsules are a prescription medicine used to treat certain types of seizures called [0m
[31mtonic-clonic [0m[1;31m([0m[31mgrand mal[0m[1;31m)[0m[31m and psychomotor [0m[1;31m([0m[31mtemporal lobe[0m[1;31m)[0m[31m seizures.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not [0m
[31mtake<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Are allergic to phenytoin or any of the [0m
[31mingredients in extended phenytoin sodium capsules. See the end of this leaflet for a complete list of ingredients in extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to [0m
[31mCEREBYX [0m[1;31m([0m[31mfosphenytoin[0m[1;31m)[0m[31m, PEGANONE [0m[1;31m([0m[31methotoin[0m[1;31m)[0m[31m, or MESANTOIN [0m[1;31m([0m[31mmephenytoin[0m[1;31m)[0m[31m. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>Have had liver problems from taking phenytoin.<[0m[31m/[0m[31mitem[0m[31m><item>Take [0m
[31mdelavirdine.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Before taking<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules, tell your healthcare provider about all of your [0m
[31mmedical conditions, including if you:<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disc"[0m[31m><item>Have or have had depression, mood problems, or suicidal thoughts or [0m
[31mbehavior<[0m[31m/[0m[31mitem[0m[31m><item>Have had an allergic reaction to a medicine similar to extended phenytoin sodium capsules called carboxamides, barbiturates, succinimides, and oxazolidinediones<[0m[31m/[0m[31mitem[0m[31m><item>Have [0m
[31mor had liver or kidney problems<[0m[31m/[0m[31mitem[0m[31m><item>Have or had an enzyme problem called porphyria<[0m[31m/[0m[31mitem[0m[31m><item>Have or had high blood sugar [0m[1;31m([0m[31mhyperglycemia[0m[1;31m)[0m[31m<[0m[31m/[0m[31mitem[0m[31m><item>Drink alcohol<[0m[31m/[0m[31mitem[0m[31m><item EXTENDED [0m
[31mPHENYTOIN SODIUM: spl_medguide_table: >Are pregnant or plan to become pregnant. Extended phenytoin sodium capsules may harm your unborn baby.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules[0m
[31mduring pregnancy, your baby is at risk for serious birth defects.<[0m[31m/[0m[31mitem[0m[31m><item>If you become pregnant while taking extended phenytoin sodium capsules, the level of phenytoin in your blood may decrease,[0m
[31mcausing your seizures to become worse. Your healthcare provider may change your dose of extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item>If you take extended phenytoin sodium capsules during pregnancy,[0m
[31myour baby is also at risk for bleeding problems right after birth. Your healthcare provider may give you and your baby medicine to prevent this.<[0m[31m/[0m[31mitem[0m[31m><item>All women of child-bearing age should talk [0m
[31mto their healthcare provider about using other possible treatments instead of extended phenytoin sodium capsules. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><item>If you are of childbearing [0m
[31mage and are not planning on getting pregnant, you should use effective birth control [0m[1;31m([0m[31mcontraception[0m[1;31m)[0m[31m while taking extended phenytoin sodium capsules.<[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Pregnancy [0m
[31mRegistry:<[0m[31m/[0m[31mcontent[0m[31m>If you become pregnant while taking extended phenytoin sodium capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy [0m
[31mRegistry. You can enroll in this registry by calling [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. <[0m[31m/[0m[31mitem[0m[31m><item>Are [0m
[31mbreastfeeding or plan to breastfeed. Phenytoin can pass into breast milk. You and your healthcare provider should decide if you will take extended phenytoin sodium capsules while you are [0m
[31mbreastfeeding. EXTENDED PHENYTOIN SODIUM: spl_medguide_table: item><[0m[31m/[0m[31mlist[0m[31m><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter [0m
[31mmedicines, vitamins, and herbal supplements. These medicines can change the levels of phenytoin in your blood.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Taking extended phenytoin sodium capsules with certain other [0m
[31mmedicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Know the medicines you take. Keep[0m
[31ma list of them and show it to your healthcare provider and pharmacist when you get a new medicine.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How should I take<[0m[31m/[0m[31mcontent[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>extended phenytoin sodium capsules?         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs[0m
[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such as phenytoin sodium, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin sodium enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy[0m
[31mRegistry. This can be done by calling the toll free number [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. Information on the registry can also be found at the website [0m
[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal [0m
[31mphenytoin exposure is associated with an increased incidence of major malformations, including orofacial clefts and cardiac defects. EXTENDED PHENYTOIN SODIUM: pregnancy: In addition, the fetal [0m
[31mhydantoin syndrome, a pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been[0m
[31mreported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, [0m
[31mincluding neuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and [0m
[31mother manifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general [0m
[31mpopulation, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. EXTENDED PHENYTOIN SODIUM: pregnancy:[0m
[31mThe background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur [0m
[31mduring pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate [0m
[31madjustment of dosage [0m[31m . However, postpartum restoration of the original dosage will probably be indicated [0m[31m. Fetal/Neonatal Adverse Reactions A potentially life-threatening bleeding disorder related to[0m
[31mdecreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother [0m
[31mbefore delivery and to the neonate after birth. EXTENDED PHENYTOIN SODIUM: pregnancy: Data Human Data Meta-analyses using data from published observational studies and registries have estimated an [0m
[31mapproximately [0m[1;31m2.4[0m[31m-fold increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital [0m
[31mhypoplasia has been reported. The fetal hydantoin syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and [0m
[31mneurodevelopmental deficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased [0m
[31mfetal growth. Malformations [0m[1;31m([0m[31mincluding craniofacial, cardiovascular, neural, limb, and digit abnormalities[0m[1;31m)[0m[31m were observed in rats, rabbits, and mice at doses as low as [0m[1;31m100[0m[31m, [0m[1;31m75[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg, [0m
[31mrespectively.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m


[31mCONTENT: EXTENDED PHENYTOIN SODIUM: drug_interactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Warfarin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Increased and decreased PT/INR responses have been [0m
[31mreported when phenytoin is co-administered with warfarin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Other<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Corticosteroids, doxycycline, estrogens, furosemide, oral [0m
[31mcontraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Drugs whose level is decreased by[0m
[31mphenytoin<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Anticoagulants<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Apixaban, dabigatran, edoxaban, rivaroxaban EXTENDED PHENYTOIN SODIUM: [0m
[31mdrug_interactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antiepileptic drugs <sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, [0m
[31mlacosamide<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antilipidemic agents<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Atorvastatin, fluvastatin, [0m
[31msimvastatin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antiplatelets<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Ticagrelor<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Antiviral [0m
[31magents<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Fosamp EXTENDED PHENYTOIN SODIUM: drug_interactions_table: [0m
[31mrenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. EXTENDED PHENYTOIN SODIUM: drug_interactions_table: Phenytoin when given [0m
[31mwith the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Calcium channel [0m
[31mblockers<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Nifedipine, nimodipine, nisoldipine, verapamil<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td><paragraph>Other<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td><paragraph>Albendazole [0m[1;31m([0m[31mdecreases active [0m
[31mmetabolite[0m[1;31m)[0m[31m, chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mXTENDED PHENYTOIN SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Extended phenytoin sodium does not have a direct reported association with increasing or decreasing the risk of renal failure in the provided label extracts. However, it is noted that the [0m
[32mmonitoring of phenytoin serum levels should be based on the unbound fraction in patients with renal or hepatic disease, or in those with hypoalbuminemia, suggesting that renal impairment can affect [0m
[32mphenytoin levels and dosing may need to be adjusted accordingly.[0m

[32mSOURCE: EXTENDED PHENYTOIN SODIUM label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mrenal or hepatic disease, or in those[0m[32m...[0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Extended phenytoin sodium does not have a direct [0m
[34mreported association with increasing or decreasing the risk of renal failure in the provided label extracts. However, it is noted that the monitoring of phenytoin serum levels should be based on the [0m
[34munbound fraction in patients with renal or hepatic disease, or in those with hypoalbuminemia, suggesting that renal impairment can affect phenytoin levels and dosing may need to be adjusted [0m
[34maccordingly.[0m

[34mSOURCE: EXTENDED PHENYTOIN SODIUM label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mrenal or hepatic disease, or in those[0m[34m...[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDAHandler has provided information that extended [0m
[32mphenytoin sodium does not have a direct reported association with increasing or decreasing the risk of renal failure according to the label extracts. It is important to note that while there isn't a [0m
[32mdirect association mentioned, the label does indicate that monitoring of phenytoin serum levels should be based on the unbound fraction in patients with renal or hepatic disease, or in those with [0m
[32mhypoalbuminemia. This suggests that renal impairment can affect phenytoin levels, and dosing may need to be adjusted in patients with renal issues.[0m

[32mGiven this information, we cannot definitively say that extended phenytoin sodium increases or decreases the risk of renal failure, as the FDA label data does not specify a direct causal relationship.[0m
[32mTherefore, the answer to the question is DO-NOT-KNOW, because the FDA label data does not specify whether extended phenytoin sodium increases or decreases the risk of renal failure.[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether extended phenytoin sodium increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the label does not report a direct association with increasing or decreasing the risk of renal failure. However, it does mention that monitoring of phenytoin serum [0m
[32mlevels should be based on the unbound fraction in patients with renal or hepatic disease, or in those with hypoalbuminemia, indicating that renal impairment can affect phenytoin levels and dosing may [0m
[32mneed to be adjusted accordingly."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether extended phenytoin sodium increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the label does not report a direct association with increasing or decreasing the risk of renal failure. However, it does mention that monitoring of phenytoin serum [0m
[34mlevels should be based on the unbound fraction in patients with renal or hepatic disease, or in those with hypoalbuminemia, indicating that renal impairment can affect phenytoin levels and dosing may [0m
[34mneed to be adjusted accordingly."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does EXTENDED PHENYTOIN SODIUM increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether extended phenytoin sodium increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that the label does not report a direct association with increasing or decreasing the risk of renal failure. However, it does mention that monitoring of phenytoin serum levels [0m
[31mshould be based on the unbound fraction in patients with renal or hepatic disease, or in those with hypoalbuminemia, indicating that renal impairment can affect phenytoin levels and dosing may need to[0m
[31mbe adjusted accordingly.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning process appears to be sound. The user has consulted FDAHandler for information on the effects of extended phenytoin sodium on renal failure risk. The response from [0m
[32mFDAHandler indicates that there is no direct association reported on the label, and the user has correctly concluded with a DO-NOT-KNOW, as there is no clear evidence to suggest an increase or [0m
[32mdecrease in risk. The user has also correctly noted the importance of monitoring phenytoin levels in patients with renal impairment, which is relevant information but does not directly answer the [0m
[32mquestion about risk. Therefore, there are no flaws in the user's reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning process appears to be sound. The user has consulted FDAHandler for information on the effects of extended phenytoin sodium on renal failure risk. The response from [0m
[34mFDAHandler indicates that there is no direct association reported on the label, and the user has correctly concluded with a DO-NOT-KNOW, as there is no clear evidence to suggest an increase or [0m
[34mdecrease in risk. The user has also correctly noted the importance of monitoring phenytoin levels in patients with renal impairment, which is relevant information but does not directly answer the [0m
[34mquestion about risk. Therefore, there are no flaws in the user's reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning process appears to be sound. The user has consulted FDAHandler for information on the effects of extended phenytoin sodium on renal failure risk. The response from [0m
[31mFDAHandler indicates that there is no direct association reported on the label, and the user has correctly concluded with a DO-NOT-KNOW, as there is no clear evidence to suggest an increase or [0m
[31mdecrease in risk. The user has also correctly noted the importance of monitoring phenytoin levels in patients with renal impairment, which is relevant information but does not directly answer the [0m
[31mquestion about risk. Therefore, there are no flaws in the user's reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-EXTENDED PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m The final answer to the question [0m[32m"Does EXTENDED [0m
[32mPHENYTOIN SODIUM increase or decrease the risk of renal failure?"[0m[32m is DO-NOT-KNOW. This conclusion is based on the information provided by FDAHandler, which indicates that the label for extended [0m
[32mphenytoin sodium does not report a direct association with increasing or decreasing the risk of renal failure. However, the label does mention the need for monitoring phenytoin serum levels in [0m
[32mpatients with renal or hepatic disease, or those with hypoalbuminemia, suggesting that renal impairment can affect phenytoin levels and that dosing adjustments may be necessary. The degree of [0m
[32mreliability of this answer is based on the specific information provided in the FDA label data, which does not establish a causal relationship between extended phenytoin sodium and renal failure risk.[0m
